Overview

A Study of Effectiveness and Safety of Abciximab in Patients With Acute Ischemic Stroke (AbESTT-II)

Status:
Terminated
Trial end date:
2005-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the effectiveness of abciximab in the treatment of acute ischemic stroke.
Phase:
Phase 3
Details
Lead Sponsor:
Centocor, Inc.
Collaborator:
Eli Lilly and Company
Treatments:
Abciximab
Antibodies, Monoclonal
Immunoglobulin Fab Fragments